Genomic analysis of atypical fibroxanthoma

Atypical fibroxanthoma (AFX), is a rare type of skin cancer affecting older individuals with sun damaged skin. Since there is limited genomic information about AFX, our study seeks to improve the understanding of AFX through whole-exome and RNA sequencing of 8 matched tumor-normal samples. AFX is a highly mutated malignancy with recurrent mutations in a number of genes, including COL11A1, ERBB4, CSMD3, and FAT1. The majority of mutations identified were UV signature (C>T in dipyrimidines). We observed deletion of chromosomal segments on chr9p and chr13q, including tumor suppressor genes such as KANK1 and CDKN2A, but no gene fusions were found. Gene expression profiling revealed several biological pathways that are upregulated in AFX, including tumor associated macrophage response, GPCR signaling, and epithelial to mesenchymal transition (EMT). To further investigate the presence of EMT in AFX, we conducted a gene expression meta-analysis that incorporated RNA-seq data from dermal fibroblasts and keratinocytes. Ours is the first study to employ high throughput sequencing for molecular profiling of AFX. These data provide valuable insights to inform models of carcinogenesis and additional research towards tumor-directed therapy.

[1]  C. Rüegg,et al.  Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin αvβ5-mediated adhesion , 2015, Oncotarget.

[2]  A. Krasinskas,et al.  CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival , 2010, Modern Pathology.

[3]  B. Paredes,et al.  CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. , 2004, Anticancer research.

[4]  Chuang Liu,et al.  A Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer Types , 2015, PLoS Comput. Biol..

[5]  S. Arron,et al.  NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis , 2014, The Journal of investigative dermatology.

[6]  J. Taylor,et al.  In vivo evidence that UV-induced C-->T mutations at dipyrimidine sites could result from the replicative bypass of cis-syn cyclobutane dimers or their deamination products. , 1993, Biochemistry.

[7]  Wyeth W Wasserman,et al.  FLAGS, frequently mutated genes in public exomes , 2014, BMC Medical Genomics.

[8]  B. Bastian,et al.  CNVkit: Copy number detection and visualization for targeted sequencing using off-target reads , 2014, bioRxiv.

[9]  Jun Wang,et al.  SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data , 2013, Genome Biology.

[10]  A. Joseph,et al.  A Pilot Feasibility Study of a Rare Skin Tumor Database , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[11]  A. Gonzalez-Perez,et al.  Functional impact bias reveals cancer drivers , 2012, Nucleic acids research.

[12]  Y-H Wu,et al.  COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer , 2014, Oncogene.

[13]  Trevor J Pugh,et al.  Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.

[14]  A. D. Dei Tos,et al.  Ultraviolet-induced p53 mutations in atypical fibroxanthoma. , 1994, The American journal of pathology.

[15]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[16]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  N. Itano,et al.  Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment , 2014, Cancers.

[18]  P. Fernández-Peñas,et al.  Atypical fibroxanthoma management: Recurrence, metastasis and disease‐specific death , 2018, The Australasian journal of dermatology.

[19]  A. Sakamoto.  Atypical Fibroxanthoma , 2008, Clinical medicine. Oncology.

[20]  Y. Tokura,et al.  Expression of Snail1 in the vimentin‐expressing squamous cell carcinoma mimicking atypical fibroxanthoma: possible involvement of an epithelial–mesenchymal transition , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[22]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[23]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[24]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[25]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[26]  Cecelia E Schmalbach,et al.  Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. , 2004, Archives of otolaryngology--head & neck surgery.

[27]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[28]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[29]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[30]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[31]  E. Eruslanov,et al.  Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. , 2012, American journal of translational research.

[32]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[33]  S. Arron,et al.  Memory regulatory T cells reside in human skin. , 2014, The Journal of clinical investigation.

[34]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[35]  David Tamborero,et al.  OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes , 2013, Bioinform..

[36]  L. Mullenders,et al.  UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. , 2001, Journal of photochemistry and photobiology. B, Biology.

[37]  Peilin Jia,et al.  Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers , 2013, Genome Medicine.

[38]  Jian Wang,et al.  Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer , 2015, Cancer and Metastasis Reviews.

[39]  T. Chan,et al.  Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy , 2015, Oncotarget.

[40]  F. Kruyt,et al.  EMT‐ and MET‐related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities , 2017, Molecular oncology.

[41]  R. Weenig,et al.  The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma , 2011, Journal of cutaneous pathology.

[42]  T. Kirchner,et al.  Epithelial-to-Mesenchymal and Mesenchymal-to-Epithelial Transition in Mesenchymal Tumors: A Paradox in Sarcomas? , 2017, Cancer research.

[43]  Curtis R. Pickering,et al.  Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma , 2014, Clinical Cancer Research.

[44]  Jing Pan,et al.  Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. , 2012, Carcinogenesis.

[45]  Christopher A. Maher,et al.  ChimeraScan: a tool for identifying chimeric transcription in sequencing data , 2011, Bioinform..

[46]  L. Liau,et al.  Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation , 2013, Nature Genetics.

[47]  Satoru Miyano,et al.  Open source clustering software , 2004 .

[48]  D. Schadendorf,et al.  TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas , 2014, Modern Pathology.

[49]  D. Weedon,et al.  Atypical fibroxanthoma: A clinicopathological study of 89 cases , 2005, The Australasian journal of dermatology.

[50]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[51]  M. Aurrand-Lions,et al.  Dual role of macrophages in tumor growth and angiogenesis , 2006, Journal of leukocyte biology.

[52]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[53]  M. Dimon,et al.  An Efficient Method for Identifying Gene Fusions by Targeted RNA Sequencing from Fresh Frozen and FFPE Samples , 2015, PloS one.

[54]  G. Leone,et al.  Role of p53 and CDKN2A Inactivation in Human Squamous Cell Carcinomas , 2007, Journal of Biomedicine and Biotechnology.

[55]  J. Dumanski,et al.  Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastoma , 1997, Nature Genetics.

[56]  L. Chin,et al.  The INK4a/ARF tumor suppressor: one gene--two products--two pathways. , 1998, Trends in biochemical sciences.